Literature DB >> 26208437

Prevalence and Incidence of Exudative Age-Related Macular Degeneration in South Korea: A Nationwide Population-Based Study.

Sang Jun Park1, Kyoung-eun Kwon2, Nam-Kyong Choi3, Kyu Hyung Park4, Se Joon Woo5.   

Abstract

PURPOSE: To determine the prevalence and incidence of exudative age-related macular degeneration (AMD) in South Korea.
DESIGN: Nationwide population-based retrospective study using data from the Korean national health claims database from 2008 through 2012. PARTICIPANTS: Entire South Korean population 40 years of age or older (n = 22,376,510).
METHODS: We accessed the national health claims database to identify exudative AMD patients using the registration program database for rare intractable diseases, which included ophthalmologist-confirmed exudative AMD, for copayment reduction. MAIN OUTCOME MEASURES: Prevalence and incidence rates of exudative AMD.
RESULTS: During the 5-year study period, 81 513 patients had exudative AMD (48.2% men) and were included in the prevalence estimates. The prevalence in the general population 40 years of age or older was 36.43 (95% confidence interval [CI], 36.18-36.68) per 10,000 people, that in men was 37.01 (95% CI, 36.65-37.38) per 10,000 people, and that in women was 35.90 (95% CI, 35.56-36.24) per 10,000 people. After excluding prevalent cases during the initial 2-year washout period, 20,196 cases were identified with incident exudative AMD during the final 3-year study period (2010-2012). The incidence in the general population 40 years of age or older was 3.02 (95% CI, 2.98-3.06) per 10,000 person-years, that in men was 3.76 (95% CI, 3.69-3.83) per 10,000 person-years, and that in women was 2.34 (95% CI, 2.29-2.39) per 10,000 person-years. The prevalence and incidence increased with advancing age and peaked at approximately 80 years of age. Both the prevalence and incidence were higher in men than in women in all age groups.
CONCLUSIONS: These detailed estimates of the nationwide, population-based prevalence and incidence of exudative AMD in an Asian population may help to understand the disease pathophysiology and to plan accordingly within the healthcare system.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26208437     DOI: 10.1016/j.ophtha.2015.06.018

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  25 in total

1.  Association of Pediatric Atopic Dermatitis and Cataract Development and Surgery.

Authors:  Hyun Sun Jeon; Mira Choi; Seong Jun Byun; Joon Young Hyon; Kyu Hyung Park; Sang Jun Park
Journal:  JAMA Ophthalmol       Date:  2018-08-01       Impact factor: 7.389

2.  Age-related differences in the prevalence of subtypes of Neovascular age-related macular degeneration in the first diagnosed eye.

Authors:  Jae Hui Kim; Young Suk Chang; Jong Woo Kim; Chul Gu Kim; Dong Won Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-07       Impact factor: 3.117

3.  Fracture risk and impact of osteoporosis in patients with Parkinson's disease: a nationwide database study.

Authors:  Tae-Lim Kim; Seong Jun Byun; Min Yong Seong; Byung-Mo Oh; Sang Jun Park; Han Gil Seo
Journal:  J Bone Miner Metab       Date:  2022-03-26       Impact factor: 2.626

4.  A Nationwide Cohort Study on the Association Between Past Physical Activity and Neovascular Age-Related Macular Degeneration in an East Asian Population.

Authors:  Tyler Hyungtaek Rim; Hong Kyu Kim; Ji Won Kim; Jihei Sara Lee; Dong Wook Kim; Sung Soo Kim
Journal:  JAMA Ophthalmol       Date:  2018-02-01       Impact factor: 7.389

5.  Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015.

Authors:  Ji-Won Kim; Sang Gyu Kwak; Hwajeong Lee; Seong-Kyu Kim; Jung-Yoon Choe; Sung-Hoon Park
Journal:  Rheumatol Int       Date:  2017-07-04       Impact factor: 2.631

6.  Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study.

Authors:  Min Sagong; Se Joon Woo; Youkyung Lee
Journal:  Clin Ophthalmol       Date:  2021-05-11

7.  Xue-fu-Zhu-Yu decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2.

Authors:  Shu-Qiu Tan; Xue Geng; Jorn-Hon Liu; Wynn Hwai-Tzong Pan; Li-Xiang Wang; Hui-Kang Liu; Lei Hu; Hsiao-Ming Chao
Journal:  BMC Complement Altern Med       Date:  2017-07-14       Impact factor: 3.659

8.  Trends in diabetic retinopathy and related medical practices among type 2 diabetes patients: Results from the National Insurance Service Survey 2006-2013.

Authors:  Su Jeong Song; Kyungdo Han; Kyung Seek Choi; Seung-Hyun Ko; Eun-Jung Rhee; Cheol-Young Park; Joong-Yeol Park; Ki-Up Lee; Kyung-Soo Ko
Journal:  J Diabetes Investig       Date:  2017-06-15       Impact factor: 4.232

Review 9.  Bringing the age-related macular degeneration high-risk allele age-related maculopathy susceptibility 2 into focus with stem cell technology.

Authors:  Shuo Sun; ZhiQing Li; Patrick Glencer; BinCui Cai; XiaoMin Zhang; Jin Yang; XiaoRong Li
Journal:  Stem Cell Res Ther       Date:  2017-06-06       Impact factor: 6.832

10.  Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase.

Authors:  Hsiao-Ming Chao; Lei Hu; Ji-Min Cheng; Xiao-Qian Liu; Jorn-Hon Liu; Wynn Hwai-Tzong Pan; Xiu-Mei Zhang
Journal:  Chin Med       Date:  2016-09-09       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.